3/19/2013 11:30:37 AM
SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), has appointed Mark Benedyk, Ph.D., to its Board of Directors. Dr. Benedyk has over 18 years of experience as a senior business development executive and consultant to life science companies, and has served as a Corporate Advisor to Amarantus since 2011. With the addition of Dr. Benedyk, the Amarantus board has four members, two of whom are considered independent directors, including Dr. Benedyk.
comments powered by